In a significant stride forward for the field of oncology, Candel Therapeutics, a clinical stage biopharmaceutical company, unveiled promising interim survival and immunological biomarker data stemming from the ongoing phase 2 trial of CAN-2409 in tandem with valacyclovir (prodrug), in conjunction with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). The announcement, made during the 2023 Society for Immunotherapy Annual Meeting, has ignited a substantial surge in Candel Therapeutics’ stock today.
At the time of this publication, Candel Therapeutics Inc stock (CADL) has witnessed a surge.
Candel Therapeutics Inc
Current Price: $0.90
Change : +0.22
Change (%): (33.31%)
Volume: 98.8K
Source: Tomorrow Events Market Data
The data revealed an estimated survival rate of 71.4% at both the 24 and 36-month marks for patients administered the CAN-2409 regimen in combination with SoC chemoradiation prior to surgery. In stark contrast, patients who underwent SoC chemoradiation before surgery experienced a markedly lower survival rate of only 16.7% at the same time intervals.
Remarkably, five out of seven patients who received CAN-2409 were still alive at the time of data cutoff, with two patients surpassing an impressive 45 months from enrollment. Conversely, only a single patient subjected to the control SoC chemotherapy arm remained alive at the data cutoff, having reached the 43-month mark.
Notably, the median overall survival rate remains unreached in patients who received CAN-2409, painting a positive picture for its efficacy. By contrast, the control arm exhibited a median overall survival rate of 12.5 months.
The data also showcased a distinct alteration in the disease course following salvage chemotherapy in the CAN-2409 arm, characterized by improved CA19-9 levels and sustained survival, which was not replicated in the control arm.
Furthermore, the results demonstrated a consistent and robust activation of the immune response subsequent to CAN-2409 administration. The treatment also exhibited a favorable tolerability profile, indicating its potential for broader application.
During the 2023 Society for Immunotherapy of Cancer Annual Meeting, Candel Therapeutics presented two posters spotlighting their enLIGHTEN Discovery Platform. The inaugural experimental agent from this platform, Alpha-201-macro1, stands as an investigational viral immunotherapy engineered to stimulate innate immune surveillance against solid tumors. This groundbreaking advancement marks a pivotal milestone in the pursuit of more effective treatments for PDAC, offering renewed hope for patients and healthcare professionals alike.
